Abstract: Biosensors, compositions comprising biosensors, methods of producing biosensors, and methods of using biosensors are disclosed. The biosensors comprise a fluorogen-activating peptide and a blocking peptide. The fluorogen-activating peptide and blocking peptide are covalently linked through a peptide linker. The blocking peptide associates with the fluorogen-activating peptide thereby blocking an active domain of the fluorogen-activating peptide when the linker is in an unmodified state. The peptide linker may contain an amino acid sequence that is specifically recognized as a modification substrate by a cognate enzyme. The fluorogen-activating peptide and the blocking peptide at least partially disassociate when the linker is modified by an enzyme, thereby allowing the fluorogen-activating peptide to bind a cognate fluorogen and modulate a fluorescence signal.

Abstract: The present invention provides nanoparticle compositions comprising, for example, a core comprising a fluorescent silane compound; and a silica shell on the core. Also provided are methods for the preparation of nanoparticle compositions including fluorescent nanoparticles, ligated-fluorescent nanoparticles, ligated-fluorescent nanoparticles having therapeutic agents, and ligated-fluorescent nanoparticles coupled or associated with an analyte.

Abstract: The present invention relates to a method to treat a product which product comprises a surface which surface includes a plasma polymer of an organic monomer wherein immobilized on said plasma polymerized surface is at least one biological entity comprising, contacting said product with an agent that promotes, either directly or indirectly, the disassociation of said entity from said product.

Abstract: This invention provides molecularly imprinted polymers (MIPs) for the detection of analytes, methods for forming the MIPs and detecting the analyte using the MIPs. The MIP comprises templated sites which are formed using a mimic of the analyte such that a reporter compound can be selectively attached at the templated sites, thus providing a site selectively tagged and templated MIP.

Abstract: A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided.

Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.

Abstract: The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative.

Abstract: Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam.

Abstract: The present invention concerns a method for detecting aggregate-forming circulating protein forms in a biological sample of human origin that may contain said aggregate-forming circulating protein forms, characterized in that it uses a non-protein agent I producing aggregation of the circulating forms of the noninfectious proteins involved in pathological aggregation processes of the central nervous system and/or a non-protein agent II for capturing the natural aggregrates of aggregate-forming circulating protein forms or the aggregates induced by said agents I.

Abstract: The invention is directed to optical sensors for measuring clinically relevant analytes, their methods of manufacture, and their various uses. In an effort to develop a dry calibration method for the optical sensors of the invention it is discovered that water content inside or in the immediate vicinity of a such a sensor can have a major impact on fluorescence intensity (i.e., a sensor's response in the dry state). Thus, one of the objectives of the invention is the elimination of the bias of sensor responses measured at different humidity environments.

Abstract: This invention provides a method of producing a large amount of an ?-form or ?-form of N-pyranosyl-tryptophan having a specified structure and preparing an antibody therefrom. The method comprises a step of allowing a pyranose compound to react with a 3-pyrazyl-indole compound in the presence of a first base to obtain a 1-pyranosyl-3-pyrazyl-indole compound, and a step of treating the 1-pyranosyl-3-pyrazyl-indole compound with an acid, treating the resultant with a hydrogenation catalyst, and further treating the resultant with a second base to synthesize N-pyranosyl-tryptophan, thereby producing an antibody therefrom.

Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.

Abstract: TGD2 proteins of Arabidopsis are proposed to be a substrate binding component of a lipid transfer complex in the inner chloroplast envelope membrane. Loss of function of this protein or other components of this complex may disrupt the endoplasmic reticulum (ER)-pathway of thylakoid lipid biosynthesis. In one embodiment, the present invention contemplates a minimal binding domain capable of specifically binding phosphatidic acid. Alternatively, the minimal binding domain may further comprise accessory binding domains that, in combination, create a complete TGD2 phosphatidic acid binding domain. Consequently, phosphatidic acid may be quantitatively detected from samples as described in the methods herein.

Abstract: Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids.

Abstract: A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided.

Abstract: A self assembling monolayer formed by the self assembling molecules is caused to bond onto the surface of a base material, and chelators are caused to bond onto the self assembling monolayer, to produce a substrate, in which the chelators are bound to the self assembling monolayer at a density within a range from 0.4/nm2 to 4/nm2. The bonding of the chelators onto the self assembling monolayer being performed within an organic solvent.

Abstract: Disclosed is a labeling substance capable of reversibly immobilizing (reversible detachment) to a solid surface and to reliably and accurately identify a target biological substance interacting with a probe substance bound to the labeling substance. A chimeric compound is provided, which includes a labeling substance L including (1) an organic compound S with a chemical structure capable of binding to a probe substance P, which can interact with a biological substance B and (2) a peptide bound to the organic compound S and specifically recognized by an antibody A, peptide and a probe substance P at least except a peptide or protein. In addition, a method for preparing the labeling substance L and a method for capturing, structurally analyzing and/or identifying the biological substance using the labeling substance L are provided.

Abstract: In an affinity-type purification, ligands dissociated from a packed bed that would otherwise leach into the solution containing the species being purified are captured by a second ligand that resides in a porous barrier downstream from the packed bed, the second ligand exhibiting an affinity-type interaction with the dissociated first ligand with sufficient specificity to avoid the undesired retention by the second ligand of species from the liquid sample or source liquid other than the species sought to be purified in the affinity column.

Abstract: Provided are an agglutination-inhibition assay and a reagent for agglutination-inhibition assay, which can be used for measuring a ligand in a sample at high sensitivity in a wide range from the low-concentration range to the high-concentration range and have good reproducibility of measurement. Specifically, provided are an agglutination-inhibition assay and a reagent for agglutination-inhibition assay, in which used are an insoluble carrier particle carrying a ligand, a specific receptor in the free-form and an insoluble carrier particle carrying a specific receptor which binds to a different site on the ligand than the receptor in the free-form.

Abstract: A molecular recognition polymer enabling the reconstruction of the recognition field for a target molecule which is produced by applying the molecular imprinting method is disclosed. A molecular recognition polymer enabling the reconstruction of the recognition field for a target molecule which has a molecule interacting with the target molecule in the polymer and in which the recognition field for a target molecule has been constructed and the above-described molecule interacting with the target molecule is detachable and replaceable. This molecular recognition polymer can be produced by synthesizing a complex of the target molecule with a molecule capable of specifically and reversibly binding to the target molecule, copolymerizing this complex with a molecule interacting with the target molecule and a crosslinking agent to give a polymer, and then detaching the target molecule and the molecule interacting with the target molecule from the polymer thus obtained.